LIFTA 20 mg (Tadalafil) is a pharmaceutical-grade oral phosphodiesterase type 5 (PDE5) inhibitor formulated as film-coated tablets, supplied in boxes of 4 tablets at 20 mg per tablet. Tadalafil is one of the most extensively researched PDE5 inhibitors in urological and cardiovascular pharmacology literature, distinguished from other compounds in its class by its notably extended plasma half-life of approximately 17.5 hours — documented in comparative PDE5 inhibitor pharmacokinetic research as the longest among approved agents in this drug class.
 
✔ Key Research Insights
Studied for its role in inhibiting phosphodiesterase type 5 enzyme activity, with documented enhancement of cyclic guanosine monophosphate (cGMP) signaling and associated smooth muscle relaxation in penile vasculature, facilitating increased blood flow and erectile function in research subjects with erectile dysfunction
Investigated for its clinical efficacy in treating erectile dysfunction across documented subject populations, with established superiority over placebo in multiple large-scale randomized clinical trials referenced in international urology guidelines
Researched for its extended plasma half-life of approximately 17.5 hours, associated with a prolonged therapeutic window relative to other PDE5 inhibitors in comparative pharmacokinetic research
Examined for its effects on lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH), with documented smooth muscle relaxation in the prostate and bladder neck via PDE5 inhibition referenced in urological research literature
Documented for its pulmonary arterial vasodilatory effects via PDE5 inhibition in pulmonary vascular smooth muscle, representing a clinically distinct research application documented in cardiovascular and pulmonary medicine literature
Referenced in international clinical guidelines for both erectile dysfunction and BPH symptom management as an established pharmacological intervention
 
📦 Product Specifications
Product: LIFTA
Also Known As: Tadalafil (Cialis analogue)
Molecule: Tadalafil
Drug Class: Phosphodiesterase Type 5 (PDE5) Inhibitor
Concentration: 20 mg per tablet
Form: Film-coated oral tablet
Volume: 4 tablets per box
Dosage considerations may vary. Consulting a qualified professional is recommended.
 
⚙ How It Works
Tadalafil is a selective inhibitor of the phosphodiesterase type 5 (PDE5) enzyme, the primary enzyme responsible for the degradation of cyclic guanosine monophosphate (cGMP) in smooth muscle tissue. In research subjects experiencing erectile dysfunction, sexual stimulation triggers the release of nitric oxide (NO) from penile endothelial and neuronal cells, which activates guanylate cyclase and elevates intracellular cGMP concentrations in corpus cavernosum smooth muscle. Tadalafil inhibits PDE5-mediated cGMP breakdown, prolonging and amplifying the cGMP-mediated smooth muscle relaxation response, facilitating increased arterial blood flow into cavernosal tissue and supporting erectile function. It is important to note that sexual stimulation is required for tadalafil to produce its erectile effects, as the compound does not directly initiate erection but rather amplifies the physiological NO-cGMP signaling cascade in response to stimulation. In the context of benign prostatic hyperplasia, PDE5 expression has been documented in prostatic stromal smooth muscle and the bladder neck, with tadalafil's inhibitory activity in these tissues associated with smooth muscle relaxation and documented improvement in lower urinary tract symptom parameters in clinical research. Tadalafil's extended plasma half-life of approximately 17.5 hours, documented in comparative PDE5 inhibitor pharmacokinetic research, distinguishes it from shorter-acting agents in the same class and supports both on-demand and once-daily low-dose administration protocols referenced in international clinical guidelines.
 
⭐ Product Overview
Pharmaceutical-grade tadalafil formulation with consistent 20 mg per tablet concentration and film-coated presentation
Established PDE5 inhibitor with one of the most extensively documented clinical profiles in erectile dysfunction and BPH pharmacotherapy literature
Distinguished within its drug class by an extended plasma half-life of approximately 17.5 hours, supporting a prolonged therapeutic window in comparative pharmacokinetic research
Dual clinical indication documented in international urology guidelines — erectile dysfunction management and lower urinary tract symptom relief in BPH
Widely referenced in urological and cardiovascular pharmacology literature under the tadalafil and Cialis designations worldwide